There’s a new medication on the market for the treatment of dementia—the first to come along in several years.

If you’re like most psychiatrists, you get your fair share of older folks who come into the office complaining of difficulties with sleep or with significant symptoms of anxiety.

Get advice on how to assess and work with patients with cognitive impairment and dementia, in an interview with Marc Agronin, MD, Geriatric Psychiatrist and Vice President of Behavioral Health and Clinical Research at Miami Jewish Health Systems.

Many medications have anticholinergic side effects, which can be particularly troublesome for the elderly.

A recent study tested an intensive weight loss program in a large group of psychiatric patients. The results were…well, read on and you decide whether they were impressive.

After reading these articles, you should be able to…

With nine other atypical antipsychotics already on the market (some of which are available as generics), did we really need another one? Given the pesky side effects of antipsychotics, maybe we did. Let’s take a look at what we know so far about Latuda (lurasidone) in an effort to figure out how to incorporate it into our clinical toolbox. Latuda was first approved by the US Food and Drug Administration (FDA) for use in schizophrenia in late 2010.

Learn about the new emphasis on community functioning for patients with schizophrenia, in an interview with Dost Ongur, MD, PhD, chief of the psychotic disorders division at McLean Hospital and an associate professor of psychiatry at Harvard Medical School.

We’ve known for some time that if your patient has a parental history of a mood disorder or suicide attempt, his or her risk of a suicide attempt increases, and a new study adds some more information that might help us prevent bad outcomes.

In December 2014, the US Food and Drug Administration (FDA) issued a safety announcement warning that the antipsychotic drug ziprasidone (Geodon) has been associated with a rare but potentially fatal skin reaction.